Domestic botulinum toxin is entering various parts of the world. Feeling limited in the domestic market, developers are targeting the U.S., Europe, and China, which are the largest markets in the world, while expanding their scope to countries such as Australia and the Middle East.

◆ Hugel is targeting Europe and North America, and China is expanding its market

According to the pharmaceutical industry on the 20th, Hugel won the license for the botulinum toxin drug Letybo developed in Canada on the 16th. It is Hugel's first North American entry. According to Hugel, the Canadian botulinum toxin market is estimated to be worth 180 billion won as of last year. Starting with Southeast A